AlphaYou
Overview
Smart money at a glance
Filings to Oct 5, 2026Net selling: insiders sold $2.3M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$2.3M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 2 added, 2 cutEven
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Market overview
Fundamentals Oct 5- Open
- $25.64
- 52-wk high
- $31.77
- High
- $25.78
- 52-wk low
- $19.30
- Low
- $25.01
- Prev close
- $25.29
- Mkt cap
- $3.16B
- P/E
- 114.4x
- Volume
- 1.78M
- Fwd P/E
- 26.4x
- Beta
- 1.50
- P/S
- 6.8x
- P/B
- 15.0x
- Profit margin
- +6.2%
- Op margin
- +12.7%
- ROE
- +15.9%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about ARQT filings
Are insiders buying or selling Arcutis Biotherapeutics Inc (ARQT) stock?
Net selling: insiders sold $2.3M and bought $0 of ARQT stock on the open market in the 90 days to Oct 5, 2026, according to SEC Form 4 filings. $879K of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Curran, Terrie (Director), who sold $984K. The latest filing was on Sep 18, 2026.
Which members of Congress have traded ARQT recently?
None. No member of Congress disclosed a ARQT trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this ARQT smart-money data?
This summary uses filings available on Oct 5, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (2)
- DS
D.E. Shaw
$44.7M
added
- CI
Citadel
$30.0M
added
Sells/Trims (1)
- SQ
Squarepoint
$11.9M
trimmed
What insiders are doing
How top traders are positioned
No tracked top-trader positions in ARQT right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in $0.02 a share above what analysts expected.
Last report
Aug 5, 2026
Period ending
Jun 30, 2026
Earnings per share
$0.09 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 5, 2026 | $0.11 / $0.09Alpha Vantage | +$0.02 beat | Unavailable | Unavailable |
| Mar 31, 2026 | May 6, 2026 | -$0.09 / -$0.06Alpha Vantage | -$0.03 miss | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 25, 2026 | $0.13 / $0.09Alpha Vantage | +$0.04 beat | Unavailable | Unavailable |
| Sep 30, 2025 | Oct 28, 2025 | $0.06 / -$0.09Alpha Vantage | +$0.15 beat | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 6, 2025 | -$0.13 / -$0.16Alpha Vantage | +18.75% beat | Unavailable | Unavailable |
| Mar 31, 2025 | May 6, 2025 | -$0.20 / -$0.21Alpha Vantage | +4.76% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 25, 2025 | -$0.09 / -$0.26Alpha Vantage | +65.95% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 6, 2024 | -$0.33 / -$0.42Alpha Vantage | +21.43% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Oct 27, 2026, in 22 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $99.2M | $129.5M | $105.4M | $129.9M |
| Cost of what it sold | $8.7M | $11.7M | $9.8M | $10.9M |
| Gross profit | $90.5M | $117.8M | $95.6M | $118.9M |
| What it spent | ||||
| Research and development | $19.6M | $20.5M | $30.6M | $20.4M |
| Sales and admin | $62.4M | $79.0M | $74.1M | $82.1M |
| Total operating expenses | $82.0M | $99.4M | $104.7M | $102.5M |
| What was left | ||||
| Operating profit | $8.5M | $18.4M | -$9.1M | $16.4M |
| Interest on debt | $3.1M | $3.0M | $4.4M | $3.4M |
| Profit before tax | $7.5M | $17.9M | -$11.2M | $15.1M |
| Tax | $80.0K | $470.0K | $93.0K | $136.0K |
| Net profit | $7.4M | $17.4M | -$11.3M | $15.0M |
| EBITDA | $11.1M | $22.1M | -$6.3M | $17.1M |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
35 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bullish
Arcutis Biotherapeutics, Inc. (ARQT) Stock Price, News, Quote & History
Leans bullishSep 30Arcutis Taps Gymnast Simone Biles for New Seb Derm and Eczema Awareness Campaign
BullishSep 29Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
BullishSep 29Trading Systems Reacting to (ARQT) Volatility
BullishSep 25Arcutis Biotherapeutics, Inc.(NasdaqGS: ARQT) added to S&P 600
NeutralSep 21Arcutis Biotherapeutics Inc. (ARQT) Stock Price | Live Quotes & Charts | NASDAQ
Leans bearishSep 19Arcutis Biotherapeutics EVP Matsuda sells $91.8k in shares
Leans bearishSep 19Arcutis Biotherapeutics EVP Masaru Matsuda Sells 3,674 Shares Under 10b5-1 Plan
NeutralSep 19
Macro
22 macro signals shaping ARQT right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results